ASLN - ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress | Benzinga
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany, at the Messe Congress Centre.
32nd European Academy of Dermatology and Venereology Congress presentation details
Abstract 1 (late-breaker) : Results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (Abstract ID 6703)
Presentation date and time: Friday, October 13, 2023, 14:45 – 15:00 CEST
Location: Hall B
Abstract 2: Downstream effects of IL-13R?1 blockade on Th2-driven inflammation and Th1 immune axis activation in atopic dermatitis (Presentation ID FC06.3)
Presentation date and time: Friday, October 13, 2023, 10:35 – 10:45 CEST
Location: Room M1 +2
Abstract 3: Neuromodulation beyond itch is blocked by targeting IL-13R?1 with eblasakimab (Poster ID P0348)
Presentation date and time: Wednesday, October 11, 2023, 09:00 CEST
Location: E-poster hall
Abstract 4: Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a ...